Skip to main content
All lobbying filings

SOLVENTUM CORPORATION

SOLVENTUM CORPORATION filed a Q1 report for SOLVENTUM CORPORATION on April 21, 2025.

Lobbying for SOLVENTUM CORPORATION

All filings by SOLVENTUM CORPORATION · Everything SOLVENTUM CORPORATION has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Expenses
$330,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Utah

Official filing document

 Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5

-Issues related to regulation of Ethylene Oxide (EtO). -Issues related to access to sterilization capacity for medical technologies. -Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and Affordable Care Act (PL 111-148). -Implementation of the Helping Hospitals Improve Patient Care Act 21st Century Cures Act (PL 114-255). -Regulations and legislation related to International Classification of Diseases, version 10 (ICD-10). -Healthcare Outcomes Act. -Issues related to the use of Artificial Intelligence. -Issues related to tariffs. -FDA appropriations.

-Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and Affordable Care Act (PL 111-148). -Implementation of the Helping Hospitals Improve Patient Care Act 21st Century Cures Act (PL 114-255). -Regulations and legislation related to International Classification of Diseases, Version 10 (ICD-10). -Healthcare Outcomes Act. -Issues related to the use of Artificial Intelligence.

Issues related to Department of Defense policy, procurement, and contracting processes for medical technology.

-Issues related to domestic and global medical supply chain resilience. -Tariff issues generally.

Issues related to Veterans Administration and Veterans Health Administration policy, procurement, and contracting processes for medical technology.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem